Compare W W Grainger Inc (GWW) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
W W Grainger Inc vs Incyte Corporation — how do they compare? W W Grainger Inc trades at $1,289.79 (market cap $59.76B), while Incyte Corporation trades at $112.79 (market cap $22.85B). The key difference: W W Grainger Inc is far larger — about 2.6× Incyte Corporation's market cap, and W W Grainger Inc pays a 0.79% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold W W Grainger Inc for 25 Days and Incyte Corporation for 33 Days on average.
| GWW | INCY | |
|---|---|---|
Market Cap | $59.76B | $22.85B |
Volume | 186,697 | 1,927,029 |
Sector | Industrials | Health |
52-Week High | $1.40K | $129.93 |
52-Week Low | $918.18 | $83.80 |
Typical Hold Time | 25 Days | 33 Days |
Enterprise Value | $61.96B | $18.35B |
Dividend Yield | 0.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
W.W. Grainger (GWW) trades at $1,268.67, up 0.41% with mixed technical signals showing bearish moving averages but neutral oscillators. The company demonstrates strong profitability with 47.92% ROE and 9.92% net margin, though valuation metrics appear elevated with a P/E of 32.34. Recent earnings show two consecutive beats, while analyst consensus leans heavily toward Hold (66.66%) with a $1,310 price target. The company continues strategic expansion with a new Oregon distribution center and technology acquisitions.
GWW presents a balanced outlook with solid fundamentals offset by premium valuation. The stock offers steady dividend growth as a Dividend King but faces headwinds from industrial sector challenges. Upside potential exists if earnings momentum continues, though current levels suggest limited near-term catalysts given the cautious analyst stance and technical resistance near $1,280-$1,303.
Incyte (INCY) trades at $112.75, down 0.61% on the day, with a bearish technical signal despite strong fundamentals. The company reported robust 2025 results with $5.14B revenue and $1.29B net income, showing significant margin expansion. Recent FDA approval for Atebrioz and pipeline progress support growth prospects beyond JAKAFI's 2029 exclusivity loss. Analyst consensus is bullish with a $132.43 price target, though technical indicators show selling pressure near key resistance.
Outlook remains positive driven by pipeline diversification and operational leverage, but near-term technical weakness and reliance on JAKAFI transition pose risks. The stock offers value with a 14.36 P/E ratio and strong profitability metrics, though investors should monitor execution on the $4B non-JAKAFI sales target and quarterly earnings consistency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About W W Grainger Inc
Grainger is a leading broad-line distributor of maintenance, repair, and operating (MRO) products. It serves millions of customers worldwide through an integrated network of branches and digital platforms.
Read more on GWW →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
